Oncotelic Therapeutics Advances Nanoparticle Drug Delivery Platform to Improve Cancer Treatment

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) was featured in a NetworkNewsAudio editorial that examines the growing emphasis on advanced drug-delivery technologies in oncology. The editorial highlights persistent challenges in cancer treatment, including drug penetration into tumors, accurate targeting of malignant cells, therapeutic resistance, and the difficulty of maintaining consistent exposure within tumor tissues. These factors are driving increased interest in nanoparticle-based and targeted delivery systems.

According to the editorial, Oncotelic is advancing its Sapu003 program and Deciparticle platform as part of a broader effort to improve the delivery and performance of existing cancer therapies. By focusing on nanotechnology-enabled delivery systems and pharmacokinetic optimization, the company is aligning with industry-wide initiatives to enhance therapeutic effectiveness and unlock additional value from established oncology treatments. The full press release is available at https://nnw.fm/MvGjV.

The company’s approach addresses key limitations of conventional cancer drugs, which often suffer from poor solubility, rapid clearance, and off-target toxicity. Nanoparticle-based delivery systems can encapsulate drugs, protect them from degradation, and release them in a controlled manner at the tumor site. This can improve the therapeutic index and reduce side effects. Oncotelic’s Deciparticle platform is designed to optimize drug pharmacokinetics and biodistribution, potentially enhancing the efficacy of both its own pipeline and partnered therapies.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, targeting high-unmet-need cancers and rare pediatric indications. The company benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Additionally, Oncotelic leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration.

Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that strengthens Oncotelic’s position in oncology and rare disease therapeutics. The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC.

The editorial underscores the importance of drug delivery innovation in oncology, as many promising therapies fail to reach their full potential due to delivery challenges. Oncotelic’s focus on nanotechnology and pharmacokinetic optimization represents a strategic effort to address these hurdles, potentially improving outcomes for patients and creating value for the company.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Oncotelic Therapeutics Advances Nanoparticle Drug Delivery Platform to Improve Cancer Treatment.

The post Oncotelic Therapeutics Advances Nanoparticle Drug Delivery Platform to Improve Cancer Treatment appeared first on citybuzz.